Danaher Co. (NYSE:DHR) Stock Position Lifted by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH grew its holdings in shares of Danaher Co. (NYSE:DHR) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,121 shares of the conglomerate’s stock after purchasing an additional 1,062 shares during the period. Danaher makes up 1.1% of Trust Co. of Toledo NA OH’s portfolio, making the stock its 17th biggest holding. Trust Co. of Toledo NA OH’s holdings in Danaher were worth $8,292,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. Benjamin Edwards Inc. grew its position in Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 38 shares in the last quarter. Wedge Capital Management L L P NC grew its holdings in shares of Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares in the last quarter. Certified Advisory Corp raised its holdings in shares of Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after acquiring an additional 40 shares in the last quarter. Meridian Financial Partners LLC grew its stake in Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. grew its stake in shares of Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 2.1 %

Shares of DHR traded up $4.82 on Monday, hitting $239.89. The company’s stock had a trading volume of 639,175 shares, compared to its average volume of 2,533,090. The firm has a market capitalization of $173.27 billion, a price-to-earnings ratio of 45.78, a P/E/G ratio of 4.32 and a beta of 0.83. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm’s fifty day moving average price is $235.67 and its 200-day moving average price is $253.73.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business earned $2.02 EPS. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, equities research analysts expect that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on DHR shares. Guggenheim began coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Stephens reissued an “overweight” rating and set a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Finally, UBS Group decreased their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.